Opioid Treatment Surge Act
This bill requires the Department of Health and Human Services to assess market-share-based fees, for the next 10 years, on drug manufacturers that have produced opioid drugs since 1999. Opioid drugs manufactured to treat opioid addiction, cancer patients, or hospice patients are, however, exempt from this assessment. All assessed fees must be used for the substance abuse prevention and treatment block grant program.